| Acceptance rate | 46% |
|---|---|
| Time to first decision | 6 months* |
| Time to decision with review | 50 days* |
*Approximate number of days
**The days mentioned above are averages and do not indicate exact durations. The process may vary for each article.
ACTA Pharmaceutica Sciencia
2017 , Vol 55 , Num 1
Novel Benzothiazole Based Imidazole Derivatives as New Cytotoxic Agents Against Glioma (C6) and Liver (HepG2) Cancer Cell Lines
1 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, 26470 Eskişehir, Turkey2 Department of Pharmaceutical Chemistry, School of Pharmacy, Medipol University, 26470 İstanbul, Turkey
3 Department of Biochemistry, Faculty of Pharmacy, Anadolu University, 26470 Eskişehir, Turkey
DOI : 10.23893/1307-2080.APS.0553 Viewed : 16084 - Downloaded : 5099 In this work, some novel N-(6-substituted-benzothiazol-2-yl)-2-[[4,5-dimethyl- 1-((p-tolyl/4-nitrophenyl)amino)-1H-imidazol-2-yl]thio]acetamide derivatives were synthesized and searched for their cytotoxic activities against C6 and HepG2 tumor cells. Among all compounds, the most active compound was determined as compound 7. It was calculated IC50 value about 15.67 µg/mL through C6 tumor cell lines and also compound 2, 4, 5, 6 were observed as good cytotoxic agents against HepG2 tumor cells. Findings about antiproliferative activity studies have encouraged the acquirement of new similar compounds in undergoing studies. Keywords : Imidazole, Benzothiazole, Cytotoxicity, Antiproliferative Activity